Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Liabilities (2018 - 2026)

Kiniksa Pharmaceuticals International's Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $25.3 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 392.91% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.3 million (up 392.91% YoY) and the FY2025 annual result came in at $18.5 million, up 916.02% from the prior year.
• Other Non-Current Liabilities was $25.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $18.5 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $25.3 million in Q1 2026 and bottomed at $260000.0 in Q2 2022.
• A 5-year average of $5.4 million and a median of $1.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 77.21% — and 2025, when it jumped 916.02%.
• Kiniksa Pharmaceuticals International's Other Non-Current Liabilities stood at $1.8 million in 2022, then climbed by 1.03% to $1.9 million in 2023, then slipped by 1.88% to $1.8 million in 2024, then soared by 916.02% to $18.5 million in 2025, then soared by 36.68% to $25.3 million in 2026.
• Business Quant data shows KNSA's Other Non-Current Liabilities at $25.3 million in Q1 2026, $18.5 million in Q4 2025, and $14.5 million in Q3 2025.